Advertisement
U.S. markets open in 2 hours 7 minutes
  • S&P Futures

    5,307.00
    -1.25 (-0.02%)
     
  • Dow Futures

    40,144.00
    0.00 (0.00%)
     
  • Nasdaq Futures

    18,496.75
    -7.00 (-0.04%)
     
  • Russell 2000 Futures

    2,140.00
    +1.60 (+0.07%)
     
  • Crude Oil

    82.35
    +1.00 (+1.23%)
     
  • Gold

    2,232.10
    +19.40 (+0.88%)
     
  • Silver

    24.75
    +0.00 (+0.01%)
     
  • EUR/USD

    1.0796
    -0.0034 (-0.31%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    12.98
    +0.20 (+1.56%)
     
  • GBP/USD

    1.2625
    -0.0013 (-0.10%)
     
  • USD/JPY

    151.3500
    +0.1040 (+0.07%)
     
  • Bitcoin USD

    70,828.22
    +716.92 (+1.02%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,956.15
    +24.17 (+0.30%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

FDA staff cites safety issues for Lilly, Incyte's rheumatoid arthritis drug

April 19 (Reuters) - The U.S. Food and Drug Administration staff on Thursday flagged concerns about potentially fatal blood clots from higher doses of Eli Lilly and Co and Incyte Corp's rheumatoid arthritis drug.

An independent panel of experts will hold an advisory committee meeting on Monday to assess the drug based on data from its developers and the analysis by FDA staff. (Reporting by Tamara Mathias in Bengaluru; Editing by Anil D'Silva)

Advertisement